The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density

The effect of psilocybin on major depressive disorder (MDD) symptom severity and synaptic density – a single dose randomized, double-blind, placebo-controlled phase 2b positron emission tomography study.

Topic Depression
Compound Placebo Psilocybin
Country Sweden
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Karolinska Institutet
KI is Sweden’s single largest centre of medical academic research which as expanded into the field of psychdelics.

Section for Affective Disorders
This company doesn't have a full profile yet, it is linked to a clinical trial.

Measures Used

Montgomery-Asberg Depression Rating Scale
A ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.